Age-related macular degeneration (AMD) is a progressive chronic disease causing visual impairment or central vision loss in the elderly. We hypothesized that successful rheopheresis would be associated with positive changes in soluble endoglin (sENG), PSCK9, alpha-2-macroglobulin (A2M), and hs-CRP levels. 31 elderly patients with the dry form of AMD, treated with rheopheresis with a follow-up period of at least 5 years and an average age of 68 ± 4 years, were evaluated. Each treated patient received a series of 8 procedures in 10 weeks and, after the 2-year period, another 2 procedures within 1 week. Then, the patients were followed up every 6 months and divided into the successfully treated and therapeutic failure group according to best-corrected visual acuity (BCVA), size of the drusen area, and the drusenoid pigment epithelium detachment (DPED). Based on the ophthalmological assessment, rheopheresis treatment was successful in 73% of AMD patients. The therapy was associated with a significant decrease in total cholesterol, LDL-C, HDL-C, apoprotein B, lipoprotein (a) levels, and rheologically important parameters, irrespective of the therapy's success or failure. The success of rheopheresis therapy was exclusively related to a significant decrease in sENG and A2M levels. Over the long term, rheopheresis prevented the decline of BCVA, reduced the DPED and area of macular drusen, and improved the preservation of an intact photoreceptor ellipsoid zone in most patients. Moreover, we showed for the first time that sENG and A2M could be potentially sensitive biomarkers of successful rheopheresis procedure, irrespective of lipid parameters changes.

Department of Biological and Medical Sciences Faculty of Pharmacy in Hradec Kralove Charles University Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Department of Immunology and Allergology Faculty of Medicine in Hradec Kralove University Hospital Hradec Kralove and Charles University Hradec Kralove Czech Republic

Department of Ophthalmology Regional Hospital Liberec Liberec Czech Republic

Faculty of Medicine in Hradec Kralove 3rd Department of Internal Medicine Metabolism and Gerontology University Hospital Hradec Kralove and Charles University Hradec Kralove Czech Republic

Faculty of Medicine in Hradec Kralove 4th Department of Internal Medicine Hematology University Hospital Hradec Kralove and Charles University Hradec Kralove Czech Republic

Faculty of Medicine in Hradec Kralove Department of Ophthalmology University Hospital Hradec Kralove and Charles University Hradec Kralove Czech Republic

Zobrazit více v PubMed

Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med.358, 2606–2617 (2008). PubMed

Roizenblatt, M., Naranjit, N., Maia, M. & Gehlbach, P. L. The question of a role for statins in age-related macular degeneration. Int. J. Mol. Sci.19, 3688 (2018). PubMed PMC

Tserentsoodol, N. et al. Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. Mol. Vis.12, 1306–1318 (2006). PubMed

Fliesler, S. J., Florman, R., Rapp, L. M., Pittler, S. J. & Keller, R. K. In vivo biosynthesis of cholesterol in the rat retina. FEBS Lett.335, 234–238 (1993). PubMed

Tserentsoodol, N. et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis.12, 1319–1333 (2006). PubMed

Klein, R. et al. Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol.132, 446–455 (2014). PubMed PMC

Lehmann, G. L. et al. Retinal pigment epithelium-secreted VEGF-A induces alpha-2-macroglobulin expression in endothelial cells. Cells11, 2975 (2022). PubMed PMC

Blazquez-Medela, A. M. et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med.8, 86 (2010). PubMed PMC

Kaitu’u-Lino, T. J. et al. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol.180, 888–894 (2012). PubMed

Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familiar hypercholesterolemia. Atherosclerosis197, 264–270 (2008). PubMed

Blann, A. D., Wang, J. M., Wilson, P. B. & Kumar, S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis120, 221–226 (1996). PubMed

Malhotra, R. et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm. Circ.3, 369–380 (2013). PubMed PMC

Leanos-Miranda, A. et al. Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. Hypertension74, 991–997 (2019). PubMed

Rathouska, J., Jezkova, K., Nemeckova, I. & Nachtigal, P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis243, 383–388 (2015). PubMed

Vitverova, B. et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis271, 15–25 (2018). PubMed

Klingel, R., Fassbender, C., Fassbender, T. & Gohlen, B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus. Apher. Sci.29, 71–84 (2003). PubMed

Borberg, H. & Tauchert, M. Rheohaemapheresis of ophthalmological diseases and diseases of the microcirculation. Transfus. Apher. Sci.34, 41–49 (2006). PubMed

Zion, I. B. et al. Pulsatile ocular blood flow: relationship with flow velocities in vessels supplying the retina and choroid. Br. J. Ophthalmol.91, 882–884 (2007). PubMed PMC

Klingel, R. et al. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther. Apher. Dial.14, 276–286 (2010). PubMed

Langrova, H. et al. Rheopheresis in the treatment of age-related macular degeneration. Cesk. Slov. Oftalmol.79, 8–24 (2022). PubMed

Rencova, E. et al. Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of age-related macular degeneration 2.5 years after rheohemapheresis. Acta Ophthalmol.91, e406-408 (2013). PubMed

Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. J. Clin. Apher.28, 145–284 (2013). PubMed

Studnicka, J. et al. Long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration. J. Ophthalmol,2013, 135798 (2013). PubMed PMC

Visek, J. et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet. J. Rare Dis.16, 110 (2021). PubMed PMC

Blaha, M. et al. Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atheroscler. Suppl.18, 140–145 (2015). PubMed

Tavori, H., Giunzioni, I., Linton, M. F. & Fazio, S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ. Res.113, 1290–1295 (2013). PubMed PMC

Augood, C. et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol.11, 117–129 (2004). PubMed

Rencova, E. et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmol.89, 463–471 (2011). PubMed

Blaha, M. et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atheroscler. Suppl.14, 179–184 (2013). PubMed

Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The seventh special issue. J. Clin. Apher.31, 149–162 (2016). PubMed

Blaha, V. et al. Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis. Atheroscler. Suppl.30, 159–165 (2017). PubMed

Pulido, J. S., Multicenter Investigation of Rheopheresis for AMDSG. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans. Am. Ophthalmol. Soc.100, 85–106 (2002). PubMed PMC

Blaha, M. et al. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atheroscler. Suppl.10, 17–20 (2009). PubMed

Rencova, E. et al. Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis. J. Ophthalmol.2015, 359747 (2015). PubMed PMC

Snow, K. K. & Seddon, J. M. Do age-related macular degeneration and cardiovascular disease share common antecedents?. Ophthalmic Epidemiol.6, 125–143 (1999). PubMed

Connelly-Smith, L. et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American society for apheresis: The ninth special issue. J. Clin. Apher.38, 77–278 (2023). PubMed

Pennington, K. L. & DeAngelis, M. M. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis.3, 34 (2016). PubMed PMC

Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis197, 264–270 (2008). PubMed

Vicen, M. et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J.33, 6099–6114 (2019). PubMed

Strasky, Z. et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ. J.75, 1747–1755 (2011). PubMed

Calabro, P., Golia, E. & Yeh, E. T. CRP and the risk of atherosclerotic events. Semin. Immunopathol.31, 79–94 (2009). PubMed

Shijo, T. et al. Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration. Int. Ophthalmol.40, 2735–2742 (2020). PubMed

Vandooren, J. & Itoh, Y. Alpha-2-macroglobulin in inflammation immunity and infections. Front. Immunol.12, 803244 (2021). PubMed PMC

Mantuano, E. et al. LDL receptor-related protein-1 regulates NFkappaB and microRNA-155 in macrophages to control the inflammatory response. Proc. Natl. Acad. Sci. U. S. A.113, 1369–1374 (2016). PubMed PMC